Novo Nordisk opens new insulin manufacturing site in Russia

Novo Nordisk Pharmaceuticals has expanded its operations with the opening of a new insulin manufacturing plant in Russia.

The company has set up a new site in Kaluga, which will be used for the formulation and filling of modern insulin for the treatment of diabetes, specifically in relation to its Penfill and FlexPen cartridges for use by the Russian market.

Chief executive of Novo Nordisk Lars Rebien Sorensen commented: "The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to ten million people have the disease, according to local studies."

Based in Kaluga's Technopark Grabtsevo, the new insulin production site will be the first of its kind in Russia, Novo Nordisk believes. It has the potential to have significant benefits for the local community, having so far resulted in the creation of approximately 150 new jobs.

The opening of the manufacturing plant in the area has been welcomed by Anatoly Artamonov, Kaluga's regional governor.